Core Insights - China is establishing itself as a strong player in the small nucleic acid drug market, with the launch of the "Zhongguancun Characteristic Industrial Park" focusing on this sector [1][2] - The new industrial park is expected to enhance Beijing's position as a global innovation hub for nucleic acid drugs, marking a significant development in the biopharmaceutical industry [1][2] Group 1: Industrial Park Overview - The "Zhongguancun Characteristic Industrial Park" is recognized as a new type of carrier for industrial innovation, aimed at gathering resources and enhancing innovation efficiency [2] - The Zhongguancun (Daxing) International Nucleic Acid Drug Industrial Park has signed contracts with 22 companies, including 11 national high-tech enterprises and 6 specialized and innovative enterprises in Beijing [2] Group 2: Market Potential and Development - The small nucleic acid drug market is seen as the third wave of modern pharmaceuticals, with significant growth potential in China [1] - The industrial park will support the development of nucleic acid drug technology through collaborations, including the establishment of a common technology platform and a joint laboratory for antisense nucleic acid technology [2]